Full-Time

Director – Clinical Operations

Confirmed live in the last 24 hours

ReCode Therapeutics

ReCode Therapeutics

51-200 employees

Develops gene therapies for respiratory diseases

Biotechnology
Healthcare

Compensation Overview

$190k - $220kAnnually

Senior

Menlo Park, CA, USA

Category
Healthcare Administration & Support
Nursing & Allied Health Professionals
Medical, Clinical & Veterinary
Requirements
  • BS/BA required with Advanced degree desirable
  • 10+ years of Clinical Operations experience in the biotech/pharma industries
  • Rare disease/orphan drug experience with Cystic Fibrosis (CF) experience a preference
  • Proven track record as Clinical Operations Program Lead
  • Clinical Operations experience across all phases of development from Phase 1-3
  • Track record of success in negotiating with CROs and representing the sponsor to internal and external stakeholders (ie site/vendor relationships)
  • Ability to build site relationships with key CF site staff/PIs globally to move clinical trials forward
  • Prior experience leading a program and study team
  • Prior experience managing direct reports
  • Demonstrated knowledge of ICH GCP
  • Regulatory inspection experience a plus
  • Strong understanding/experience in rare disease patient recruitment and site/patient engagement strategies
  • Highly responsive and proactive team player
  • Ability to have growth mindset when problem solving complex issues
  • Strong organizational skills and able to prioritize and manage multiple ongoing projects simultaneously
  • Excellent communication and interpersonal skills with the ability to collaborate and work effectively in a cross-functional, fast-paced environment.
  • Champion for change within a fast-growing company/department
  • Positive attitude with an emphasis on team-based problem-solving approach
Responsibilities
  • Independently/proactively manage all aspects of multiple clinical studies within a complex program, including the study team and all external vendors.
  • Provide oversight and guidance to internal Clinical Operations team.
  • Accountable for clinical operations timelines and working closely with Core Team Program Manager to keep internal/external teams on track.
  • Maintain expert knowledge of Clinical Development programs. Can independently interpret data and make recommendations on next steps.
  • Liaise with clinical site staff and Investigators as appropriate to ensure optimal Sponsor-site relationships.
  • Develop and ensure execution of activities outlined in various study plans (sponsor oversight, monitoring, deviation, training, and study communication plans).
  • Co-monitor or monitor studies if needed for the program.
  • Drive communication and escalate issues to Head of Clinical Operations as appropriate, Clinical Sub Team.
  • Navigate team structure (Study execution meeting and clinical meetings) and decision makers to independently resolve issues and escalate challenges/obstacles effectively.
  • Participate in preparation of regulatory filings (e.g. US IND, EU CTIS, UK MHRA) as needed.
  • Experience managing/collaborating with CROs and other study vendors.
  • Support and lead Study Execution Team meetings.
  • Lead cross-functional teams, pro-actively shaping team dynamics to support collaboration and accountability.
  • Oversee performance, manage, and serve as point of contact for all CROs and vendors.
  • Manage vendor scope and budgets in alignment with study (program) budget.
  • Manage study resources, internally and externally, to optimize performance to study deliverables.
  • Demonstrate ability to mitigate and escalate changes in scope appropriately.
  • Create and manage standardized clinical trial tools, processes, and SOPs.
  • Be accountable for clinical trial enrollment (ie develop recruitment strategies) and risk mitigations.
  • Ability to be accountable for decisions made as Clinical Operations lead, and escalate issues/risks in real time.
  • Experience managing/mentoring direct/indirect reports.

ReCode Therapeutics develops gene therapy solutions aimed at treating complex respiratory diseases, specifically cystic fibrosis and primary ciliary dyskinesia. Their approach involves utilizing advanced drug development techniques to create therapies that can effectively target and restore function in patients suffering from these conditions. What sets ReCode apart from its competitors is its focus on overcoming challenges related to targeted delivery of therapies, which is crucial for the effectiveness of gene treatments. The company's goal is to enhance the quality of life for patients with unmet medical needs in respiratory health by advancing their therapies through rigorous clinical trials and eventually bringing them to market.

Company Stage

Grant

Total Funding

$338M

Headquarters

Dallas, Texas

Founded

2015

Growth & Insights
Headcount

6 month growth

0%

1 year growth

-3%

2 year growth

39%
Simplify Jobs

Simplify's Take

What believers are saying

  • ReCode's recent $80 million Series A and additional $50 million Series B financing rounds indicate strong investor confidence and financial stability.
  • The appointment of experienced industry veterans like Dean J. Mitchell and John G. Matthews strengthens the company's leadership and clinical development capabilities.
  • Participation in high-profile conferences and strategic collaborations position ReCode as a thought leader in the genetic medicines space.

What critics are saying

  • The clinical-stage nature of ReCode's therapies means that they are still subject to the high risks and uncertainties of clinical trials.
  • The competitive landscape in genetic medicines and mRNA-based therapies is intense, with numerous well-funded competitors.

What makes ReCode Therapeutics unique

  • ReCode Therapeutics leverages its proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform for highly precise and targeted delivery of genetic medicines, setting it apart from competitors.
  • The company's focus on inhaled mRNA-based therapies for diseases like cystic fibrosis and primary ciliary dyskinesia addresses unmet needs in the respiratory disease market.
  • Strategic collaborations with leading gene editing companies like Intellia Therapeutics enhance ReCode's capabilities in developing novel genomic medicines.

Help us improve and share your feedback! Did you find this helpful?